Journal · Nuclear Medicine · Updated 15 November 2026
Clinical Nuclear Medicine
Read Clinical Nuclear Medicine articles on DeepDyve. No university library needed.
Clinical Nuclear Medicine, published by Wolters Kluwer, has covered nuclear medicine and molecular imaging since 1976. Its papers include original studies and many short case reports on PET/CT findings, newer imaging tracers and radioligand therapies for cancer. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Wolters Kluwer.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Clinical Nuclear Medicine at a glance
- Full title
- Clinical Nuclear Medicine
- Abbreviation (NLM)
- Clin Nucl Med
- Publisher
- Wolters Kluwer
- Print ISSN
- 0363-9762
- Online ISSN (eISSN)
- 1536-0229
- First published
- 1976
- Subjects
- Nuclear Medicine
- Access model
- Hybrid: subscription, with an open access option
- On DeepDyve
- Research articles; availability varies by article
Ways to access Clinical Nuclear Medicine
4% of the articles Clinical Nuclear Medicine published from January 1 to November 14, 2026 are open access and free to read. For the rest, check a library, look for NIH-funded papers in PubMed Central, or read them on DeepDyve.
- Open access articles. 4% of Clinical Nuclear Medicine articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Clinical Nuclear Medicine. Check its journal list and whether it offers remote access.
- DeepDyve. Read Clinical Nuclear Medicine articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: NIH Public Access Policy; open access share from Crossref license data.
Recent Clinical Nuclear Medicine research worth reading
Published March to September 2026. Summaries describe what the authors report.
-
Intrathoracic Herniated and Infected Pancreatic Pseudocyst
The authors describe a 40-year-old man in whom FDG PET/CT showed infected pancreatic pseudocysts extending into the chest through a hiatal hernia, treated with transgastric drainage of 200 mL of pus and antibiotics, after which the cysts regressed.
Wehmann et al. · Clinical Nuclear Medicine, published online March 31, 2026 · DOI 10.1097/rlu.0000000000006462
-
Experience With 177Lu-FAPI-2286 Therapy as the Last Resort in a Patient With Metastatic Colon Cancer
The authors describe a 49-year-old man with metastatic colon cancer treated with 177Lu-FAPI-2286 radioligand therapy as a last resort, whose tumor marker kept rising and who died 10 weeks later, and suggest that earlier treatment might be more useful.
Clinical Nuclear Medicine, August 2026 · DOI 10.1097/rlu.0000000000006230
-
68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis
In a 67-year-old woman with newly diagnosed metastatic breast cancer, the authors report that Trivehexin PET, which targets αvβ6 integrin, showed lesions with a higher target-to-background ratio than FDG PET and revealed additional metastatic sites.
Clinical Nuclear Medicine, August 2026 · DOI 10.1097/rlu.0000000000006178
-
Upfront 177Lu-PSMA Radioligand Therapy With Concurrent Androgen-deprivation Therapy Producing Dramatic Clinical and Biochemical Response
The authors describe a 72-year-old man with extensive bone metastases from prostate cancer who received upfront 177Lu-PSMA therapy with androgen-deprivation therapy in a trial, with all PSMA-avid lesions resolving, a 99% fall in PSA, and disease control at 8 months.
Clinical Nuclear Medicine, September 2026 · DOI 10.1097/rlu.0000000000006411
-
FDG-Avid But FAPI-Negative Intramucosal Carcinoma in a Colorectal Adenoma
The authors describe a man in his 70s whose early colon carcinoma, confined within an adenoma, showed intense uptake on FDG PET but none on FAPI PET, and suggest FAPI imaging may miss early lesions that lack a fibrous tissue reaction.
Adaniya et al. · Clinical Nuclear Medicine, published online May 11, 2026 · DOI 10.1097/rlu.0000000000006532
Questions about Clinical Nuclear Medicine
How can I read Clinical Nuclear Medicine articles without a subscription?
4% of Clinical Nuclear Medicine articles published from January 1 to November 14, 2026 are open access and free to read. Your library may also subscribe. DeepDyve lets you read Clinical Nuclear Medicine articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Clinical Nuclear Medicine?
Clinical Nuclear Medicine’s NLM (PubMed) abbreviation is Clin Nucl Med.
What is the ISSN of Clinical Nuclear Medicine?
The print ISSN is 0363-9762 and the online ISSN is 1536-0229.
Is Clinical Nuclear Medicine open access?
Clinical Nuclear Medicine is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 17 of 487 Clinical Nuclear Medicine articles (4%) carry a Creative Commons license, per Crossref.
Clinical Nuclear Medicine articles on DeepDyve are licensed from Wolters Kluwer. Journal facts as of 15 November 2026.
Start reading Clinical Nuclear Medicine today
One month free, then less than $2 a day. Clinical Nuclear Medicine, plus millions of articles from thousands of journals.
